Last reviewed · How we verify
Nasonex Nasal Spray
Nasonex (mometasone furoate) is a intranasal corticosteroid that reduces inflammation in the nasal passages by binding to glucocorticoid receptors.
Nasonex (mometasone furoate) is a intranasal corticosteroid that reduces inflammation in the nasal passages by binding to glucocorticoid receptors. Used for Allergic rhinitis (seasonal and perennial), Nasal polyps.
At a glance
| Generic name | Nasonex Nasal Spray |
|---|---|
| Also known as | Mometasone furoate nasal spray |
| Sponsor | National University of Malaysia |
| Drug class | Intranasal corticosteroid |
| Target | Glucocorticoid receptor |
| Modality | Small molecule |
| Therapeutic area | Allergy/Immunology |
| Phase | Phase 3 |
Mechanism of action
Mometasone furoate is a potent topical corticosteroid that suppresses local inflammatory responses in the nasal mucosa. It inhibits the release of inflammatory mediators (cytokines, chemokines, adhesion molecules) and reduces recruitment of inflammatory cells, thereby decreasing nasal congestion, rhinorrhea, and sneezing associated with allergic rhinitis.
Approved indications
- Allergic rhinitis (seasonal and perennial)
- Nasal polyps
Common side effects
- Headache
- Pharyngitis
- Epistaxis
- Nasal irritation
- Dysgeusia
Key clinical trials
- Long-term Safety and Efficacy Evaluation of Lunsekimig in Adult Participants With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) Who Completed a Previous Lunsekimig CRSwNP Study (PHASE2)
- A Phase 3 Study to Assess the Efficacy, Safety, and Tolerability of Itepekimab (Anti-IL-33 mAb) in Participants With Inadequately-controlled Chronic Rhinosinusitis With Nasal Polyps (PHASE3)
- A Phase 3 Study to Assess the Efficacy, Safety, and Tolerability of Itepekimab (Anti-IL-33 mAb) in Participants With Inadequately-controlled Chronic Rhinosinusitis With Nasal Polyps (PHASE3)
- Long-term Safety and Efficacy of TQH2722 Injection in the Treatment of Chronic Sinusitis With or Without Nasal Polyps (PHASE2)
- A Proof-of-concept Study of Lunsekimig Compared With Placebo in Adults With Chronic Rhinosinusitis With Nasal Polyps (PHASE2)
- Research on Underlying Causes of Long-term Use of Nasal Decongestants and the Structured Withdrawal of the Decongestant (PHASE4)
- A Extension Clinical Study of TQC2731 Injection in the Treatment of Chronic Sinusitis With Nasal Polyps (PHASE2)
- A Proof-of-Concept Study to Assess the Efficacy, Safety and Tolerability of Itepekimab (Anti--IL-33 mAb) in Participants With Chronic Rhinosinusitis Without Nasal Polyps (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Nasonex Nasal Spray CI brief — competitive landscape report
- Nasonex Nasal Spray updates RSS · CI watch RSS
- National University of Malaysia portfolio CI